What is the 13F Pro Quality Score for IMNM?

13F Pro ranks Immunome Inc. (IMNM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IMNM's current score at https://13fpro.ai/company/IMNM (free sign-up required for the full ranking).

Which hedge funds own the most IMNM stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of IMNM include T. Rowe Price Investment Management,, FMR, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/IMNM as soon as new 13F filings post.

Where does 13F Pro source IMNM data?

All Immunome Inc. fundamentals and ownership data come directly from SEC EDGAR. Immunome Inc. files with the SEC under CIK 1472012. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IMNM in?

Immunome Inc. (IMNM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IMNM research updated on 13F Pro?

IMNM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Immunome Inc.(IMNM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1472012 IMNM stock profile & AI dashboard →

13F Pro Quality Score

25.3/100

Rank #2,770 of 3,064 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

30.0/100

Profitability

30.0/100

Balance Sheet

5.9/100

Earnings Quality

19.5/100

Free Cash Flow

30.0/100

Institutional Flow

33.2/100

Revenue Scale

30.0/100

Dilution Risk

1.2/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why IMNM Scores 25/100

exact factor attribution · 2026-08-23

IMNM's composite is held back by capital efficiency and revenue growth. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

-0.8 pts

33th pct

Earnings growth

-1.0 pts

30th pct

Shareholder dilution

-2.4 pts

1th pct

Profitability

-3.0 pts

30th pct

Free cash flow

-3.0 pts

30th pct

Scale

-3.0 pts

30th pct

Earnings quality

-3.0 pts

20th pct

Revenue growth

-4.0 pts

30th pct

Capital efficiency

-4.4 pts

6th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in IMNM

Events flagged as statistical outliers against IMNM's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-11
IMNM quality score jumped 18 points (6→24) on a new filing
View source filing →

IMNM Stock Analysis & AI Quality Score

Data updated 2026-08-23

AI stock analysis and institutional research for Immunome Inc. (IMNM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IMNM at 25.3/100 on a 32-signal composite quality model, placing it at rank #2,770 of 3,064 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (5.9) and earnings quality (19.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Immunome Inc. reports net income of $-73.1M, free cash flow of $-63.9M. Top institutional holders of IMNM by reported 13-F value include T. Rowe Price Investment Management, FMR, BlackRock, based on the most recent SEC filings. IMNM trades on the Nasdaq exchange and files with the SEC under CIK 1472012. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMNM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Immunome Inc. directly from SEC EDGAR. Immunome Inc.'s 13F Pro composite quality score has ranged between 6 and 25 since 2024, currently 25.3 — a stable long-term trajectory across 51 quarterly and live scoring snapshots.

✦

Fun facts about Immunome Inc.

Quirks, history, and lore behind IMNM — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · focused on oncology · listed on Nasdaq · headquartered in Maryland.
2
The Numbers
A micro-cap with minimal revenue and a pipeline still working its way through clinical trials — the business model is science first, profits (much) later.
3
The History
Founded in the 2010s, the company was rebuilt around a bold idea: use memory B-cell technology to find antibody drug candidates the human immune system already knows how to make.
4
The Secret
Its platform essentially interrogates cancer survivors' immune cells to discover which antibodies their bodies naturally deployed — then turns those into drugs.
5
The Lore
The company inked a collaboration deal with Pfizer to co-develop cancer antibody therapies, a partnership that put a small Maryland biotech on much bigger radar screens.
6
The Giveaway
Its very name is a mashup of "immune" and "genome" — and its ticker is a tidy four-letter advertisement for what it does: IMNM.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$0.00

Net Income

Q2 2026

$-73.1M

Free Cash Flow

Q2 2026

$-63.9M

ROIC

Q2 2026

-59.5%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-23.2% YoY

$6.9MFY 2025

FY22 —FY23 $14.0MFY24 $9.0MFY25 $6.9M

Net Income

+27.5% YoY

$-212.4MFY 2025

FY22 $-36.9MFY23 $-106.8MFY24 $-293.0MFY25 $-212.4M

Operating Income

+26.7% YoY

$-224.1MFY 2025

FY22 $-36.9MFY23 $-109.5MFY24 $-305.8MFY25 $-224.1M

EPS (Diluted)

+51.4% YoY

$-2.43FY 2025

FY22 $-3.09FY23 $-5.38FY24 $-5.00FY25 $-2.43

Total Assets

+184.4% YoY

$683.2MFY 2025

FY22 $24.0MFY23 $148.5MFY24 $240.2MFY25 $683.2M

Total Debt

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Op. Cash Flow

-72.3% YoY

$-190.9MFY 2025

FY22 $-28.7MFY23 $-7.6MFY24 $-110.8MFY25 $-190.9M

Free Cash Flow

-70.1% YoY

$-200.6MFY 2025

FY22 $-28.9MFY23 $-8.4MFY24 $-118.0MFY25 $-200.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$6.9M -23.2%	$9.0M -35.5%	$14.0M	—	—	—
Net Income	$-212.4M +27.5%	$-293.0M -174.3%	$-106.8M -189.5%	$-36.9M -49.3%	$-24.7M -38.5%	$-17.8M
Operating Income	$-224.1M +26.7%	$-305.8M -179.2%	$-109.5M -196.8%	$-36.9M -46.4%	$-25.2M -105.6%	$-12.3M
EPS (Diluted)	$-2.43 +51.4%	$-5.00 +7.1%	$-5.38 -74.1%	$-3.09 -44.4%	$-2.14 +59.3%	$-5.26
Total Assets	$683.2M +184.4%	$240.2M +61.7%	$148.5M +517.7%	$24.0M -58.5%	$57.9M +30.1%	$44.5M
Total Debt	—	—	—	—	—	$866.0K
Operating Cash Flow	$-190.9M -72.3%	$-110.8M -1364.0%	$-7.6M +73.6%	$-28.7M -57.4%	$-18.2M -50.2%	$-12.1M
Free Cash Flow	$-200.6M -70.1%	$-118.0M -1304.5%	$-8.4M +71.0%	$-28.9M -58.1%	$-18.3M -43.9%	$-12.7M

Get alerted when IMNM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Immunome Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IMNM

T. Rowe Price Investment Management, Inc.
$417.0M19,676,883 sh
FMR LLC
$360.0M16,987,553 sh
BlackRock, Inc.
$186.6M8,805,492 sh
STATE STREET CORP
$116.4M5,494,625 sh
WELLINGTON MANAGEMENT GROUP LLP
$110.4M5,210,216 sh
Redmile Group, LLC
$104.1M4,911,590 sh
PRIMECAP MANAGEMENT CO/CA/
$97.1M4,581,431 sh
VANGUARD CAPITAL MANAGEMENT LLC
$96.4M4,551,289 sh
DRIEHAUS CAPITAL MANAGEMENT LLC
$92.1M4,346,139 sh
Enavate Sciences GP, LLC
$76.6M3,613,799 sh

Fund	Value	Shares
T. Rowe Price Investment Management, Inc.	$417.0M	19,676,883
FMR LLC	$360.0M	16,987,553
BlackRock, Inc.	$186.6M	8,805,492
STATE STREET CORP	$116.4M	5,494,625
WELLINGTON MANAGEMENT GROUP LLP	$110.4M	5,210,216
Redmile Group, LLC	$104.1M	4,911,590
PRIMECAP MANAGEMENT CO/CA/	$97.1M	4,581,431
VANGUARD CAPITAL MANAGEMENT LLC	$96.4M	4,551,289
DRIEHAUS CAPITAL MANAGEMENT LLC	$92.1M	4,346,139
Enavate Sciences GP, LLC	$76.6M	3,613,799

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IMNM on your watchlist

Track score changes the day Immunome Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IMNM a good stock to buy?

13F Pro's AI-powered analysis of Immunome Inc. (IMNM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IMNM are available on the IMNM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. IMNM is classified as a mid company.

Which hedge funds own IMNM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IMNM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Immunome Inc.'s investment landscape.